Abstract
1 Steady state plasma concentrations (SSPCs) of acetanilide (AA) and its metabolite, paracetamol (PL), were studied in 27 healthy volunteer subjects before and at the end of an 11-day exposure to phenytoin (DPH). Plasma concentrations of DPH were estimated. Plasma concentrations of DPH varied from 5.1 to 20.4 microgram ml-1 (mean +/- s.e.mean 12.2 +/- 0.9). 2 The SSPC of AA before exposure to DPH varied from 0.06 to 0.67 microgram ml-1 (mean +/- s.e.mean 0.24 +/- 0.02), and following exposure from 0.03 to 0.47 microgram ml-1 (mean +/- s.e.mean 0.15 +/- 0.02). 3 The SSPC of PL before exposure to DPH varied from 1.2 to 4.4 microgram ml-1 (mean +/- s.e.mean 2.7 +/- 0.13), and following exposure from 1.1 to 3.8 microgram ml-1 (mean +/- s.e.mean 2.2 +/- 0.13). 4 SSPCs of AA and of PL decreased significantly during DPH administration (P less than 0.01 for AA, P less than 0.001 for PL). 5 Correlations were observed between the SSPCs of the drugs measured, suggesting a common influence on their kinetics. 6 Similarity was observed between the changes in plasma levels of AA and PL following DPH ingestion. There was, however, wide inter-subject variability in this regard. In some subjects no change was observed even though they had DPH demonstrable in their plasma. Consequently it may be speculated that the effects of DPH may be under genetic control.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Baty J. D., Robinson P. R., Wharton J. A method for the estimation of acetanilide, paracetamol and phenacetin in plasma and urine using mass fragmentography. Biomed Mass Spectrom. 1976 Apr;3(2):60–63. doi: 10.1002/bms.1200030204. [DOI] [PubMed] [Google Scholar]
- Cunningham J. L., Bullen M. F., Evans D. A. The pharmacokinetics of acetanilide and of diphenylhydantoin sodium. Eur J Clin Pharmacol. 1974 Oct 4;7(6):461–466. doi: 10.1007/BF00560359. [DOI] [PubMed] [Google Scholar]
- Davies D. S., Thorgeirsson S. S. Individual differences in the plasma half-lives of lipid soluble drugs in man. Acta Pharmacol Toxicol (Copenh) 1971;29 (Suppl 3):181–190. doi: 10.1111/j.1600-0773.1971.tb03298.x. [DOI] [PubMed] [Google Scholar]
- Fletcher K. A., Evans D. A., Canning M. V. Inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes: a study of repeatability. J Med Genet. 1978 Jun;15(3):182–188. doi: 10.1136/jmg.15.3.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hammer W., Mårtens S., Sjöqvist F. A comparative study of the metabolism of desmethylimipramine, nortriptyline, and oxyphenylbutazone in man. Clin Pharmacol Ther. 1969 Jan-Feb;10(1):44–49. doi: 10.1002/cpt196910144. [DOI] [PubMed] [Google Scholar]
- Kadar D., Inaba T., Endrenyi L., Johnson G. E., Kalow W. Comparative drug elimination capacity in man-glutethimide, amobarbital, antipyrine, and sulfinpyrazone. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):552–560. doi: 10.1002/cpt1973144part1552. [DOI] [PubMed] [Google Scholar]
- Kellermann G., Luyten-Kellermann M., Horning M. G., Stafford M. Elimination of antipyrine and benzo[a]pyrene metabolism in cultured human lymphocytes. Clin Pharmacol Ther. 1976 Jul;20(1):72–80. doi: 10.1002/cpt197620172. [DOI] [PubMed] [Google Scholar]
- Kellermann G., Luyten-Kellermann M., Shaw C. R. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am J Hum Genet. 1973 May;25(3):327–331. [PMC free article] [PubMed] [Google Scholar]
- Vesell E. S., Page J. G. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. J Clin Invest. 1969 Dec;48(12):2202–2209. doi: 10.1172/JCI106186. [DOI] [PMC free article] [PubMed] [Google Scholar]